Cancer Biology & Genetics Program, Memorial Sloan-Kettering Cancer Center, New York, NY, USA.
Cell Cycle. 2012 Mar 15;11(6):1076-80. doi: 10.4161/cc.11.6.19451.
The functional annotation of the cancer genome can reveal new opportunities for cancer therapies. The wealth of genomic data on various cancers has not yet been mined for clinically and therapeutically useful information. We use cross-comparisons of genomic data with the results of unbiased genetic screens to prioritize genomic changes for further study. In this manner, we have identified a soluble variant of the ephrin receptor A7 (EPHA7 (TR) ) as a tumor suppressor that is lost in lymphoma. We also developed antibody-based delivery to restore this tumor suppressor to the cancer cells in situ. We will discuss our strategy of screening genomic data, specific findings concerning EPHA7 and the potential for future discoveries.
癌症基因组的功能注释可以揭示癌症治疗的新机会。各种癌症的基因组数据尚未被挖掘出具有临床和治疗意义的信息。我们使用基因组数据与无偏遗传筛选结果的交叉比较,来优先考虑进一步研究的基因组变化。通过这种方式,我们已经确定了一种 Ephrin 受体 A7(EPHA7(TR))的可溶性变体作为肿瘤抑制因子,该因子在淋巴瘤中丢失。我们还开发了基于抗体的递送来将这种肿瘤抑制因子原位递送到癌细胞中。我们将讨论我们筛选基因组数据的策略、关于 EPHA7 的具体发现以及未来发现的潜力。